Vitamin deficiency linked to Multiple Sclerosis through genetic analysis

vitamidPrior studies have determined a link between vitamin D deficiency and metabolic sclerosis. A new study from McGill University in Canada has determined that vitamin D deficiency caused by genetic expression is linked to increasing the risk of MS by 50%.

The study examined 14,498 people with multiple sclerosis and 24,091 healthy controls and used a Mendelian randomization technique to analyze the association between genetically reduced vitamin D levels, (measured by an existing levels of 25-hydroxyvitamin D, the clinical determinant of  status). The scientists determined that a genetic decrease in the  level by one standard deviation was associated with a 2-fold increased risk of  and recommend- further clinical trials.

Previous studies have confirmed the link between the onset of  (MS) and low levels of. The  estimates that 2.5 million people are affected by . MS is a central nervous system disease characterised by problems with muscle control and strength, vision, balance, feeling, and thinking. The new study is one of the first to examine  levels from the onset of symptoms of their disease.

“Because low  levels are common and can be easily and safely increased by oral supplementation, these findings may contribute to better outcomes for many MS patients,” said lead author , professor of epidemiology and  at  (HSPH).

“The benefits of  appeared to be additive to those of interferon beta-1b, a drug that is very effective in reducing MS activity. The findings of our study indicate that identifying and correcting insufficiency should become part of the standard of care for newly diagnosed MS patients,” said Ascherio.

The study consisted of analyzing data obtained from 465 MS patients from 18 European countries, Israel, and Canada who enrolled in 2002 and 2003 in the BENEFIT (Betaseron in Newly Emerging  for Initial Treatment) trial, which was aimed at comparing the effectiveness of early versus late interferon beta-1b in treating the disease. The researchers examined levels of  correlated with disease symptoms and progression over a period of five years.

It was found that early stage MS patients with adequate levels of  had a 57% lower rate of new brain lesions, a 57% lower relapse rate, and a 25% lower yearly increase in lesion volume than those with lower levels of . The study also confirmed that loss in brain volume, was lower among patients with adequate  levels.


, Kassandra L. Munger, Rick White, Karl Köchert, Kelly Claire Simon, Chris H. Polman, Mark S. Freedman, Hans-Peter Hartung, David H. Miller, Xavier Montalbán, Gilles Edan, Frederik Barkhof, Dirk Pleimes, Ernst-Wilhelm Radü, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl.  as an Early Predictor of Activity and Progression. JAMA Neurology, 2014; DOI: 10.1001/jamaneurol.2013.5993

Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Leong A, et al.  and Risk of : A Mendelian  Study. PLoS Med, 2015 DOI: 10.1371/journal.pmed.1001866

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s